Fig. 4: The presence of adverse stromal interactions (ASI + ) is a distinct high-risk patient subgroup and occurs in patients with newly diagnosed myeloma. | Nature Communications

Fig. 4: The presence of adverse stromal interactions (ASI + ) is a distinct high-risk patient subgroup and occurs in patients with newly diagnosed myeloma.

From: Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes

Fig. 4

a Bar graphs and heat map showing the distribution of high-risk characteristics (ISS International Staging System, LDH Elevated lactate dehydrogenase, HRT Presence of a high-risk IGH translocation, −17p = Del(17p), +1q = Gain(1q), TMB high tumor mutational burden) among 623 patients with newly diagnosed myeloma ranked by the extent of adverse stromal interactions (Σ ASI). b Bar graphs showing the distribution of demographic characteristics (MHD = Multi-hit disease; double- or triple-hit) of patients stratified by ASI + . The scatter plot indicates the statistical significance for each two-way comparison (ASI+ versus ASI–) after adjusting for multiple comparisons (Fisher’s exact test).

Back to article page